该集团是一家即将进入商业化阶段的生物製药公司。同源康生物为一家非全资附属公司，专注于双抗、 三抗及ADC，独立于集团的核心业务及营运。增资及先前增资预计将有助于为同源康生物产生营运资 金，同源康生物是一家处于早期阶段的初创企业，预计在实现商业化之前，其在不久的将来将有大量的 资金需求。因此，该等交易将使集团能够将其资源集中于集团营运的其他方面，使集团能够更好地管理 其营运，同时保留于同源康生物的重大权益及参与程度。 同源康医药-B(02410)公布，于2026年2月27日(交易时段后)，现有股东(包括该公司)、同源康生物及认购 人(深圳创新资本、宁波红土、衢州启真、衢州高质量发展、长兴同源及深圳国海中恒)订立增资合同， 据此，订约方同意以总代价约人民币8350万元增加同源康生物的注册资本约人民币649万元。增资完成 后，同源康生物的总注册资本将由人民币1400万元增加至约人民币2049万元，而公司于同源康生物的权 益将由约57.14%减少至39.03%，且同源康生物将不再为集团的附属公司。 ...

智通财经APP讯，恒昌集团国际(01421)发布截至2025年12月31日止6个月的中期业绩，该集团取得收益 5662.7万港元，同比增长3.61%;公司拥有人应占亏损1130.6万港元，同比减少30.68%;每股基本亏损6.8港 仙。 公告称，公司拥有人应占亏损及母公司普通股权持有人应占的每股基本亏损为6.8港仙的变动主要由于 太阳能电业务分部业绩好转产生亏损约570万港元(截至2024年12月31日止六个月：亏损820万港元);(2) 美容及保健业务分部业绩好转产生亏损170万港元(截至2024年12月31日止六个月：亏损 300万港元);及 (3)公司及其他未分配开支增加至约860万港元(截至2024年12月31日止六个月： 760万港元)的综合影 响。 ...

来源：渤海银行 近日，我行在津召开2026年工作会议，全面落实党的二十大和二十届历次全会精神，深入学习贯彻习近 平总书记关于金融工作系列重要论述和视察天津重要讲话精神，认真落实中央金融监管部门和市委市政 府工作要求，总结全行2025年工作情况，全面部署2026年重点任务。党委书记、董事长王锦虹围绕推动 转型发展的主旨作了讲话，党委副书记、行长屈宏志作经营管理情况报告，党委副书记凌颖杰主持会 议。 会议认为，我行砥砺奋进改革转型，2025年实现了更加系统的发展成效。党建引领旗帜更加鲜明，错位 发展路径日益清晰，内涵发展持续纵深推进，风控合规体系迭代升级，科技赋能基础焕新起步，营收净 利润保持"双增"势头，国际评级展望维持稳定。全行上下同心协力，实现了"十四五"圆满收官，也 为"十五五"开局奠定坚实的基础。 会议指出，2026年是我行决战决胜转型发展的关键之年。全行必须坚持以习近平新时代中国特色社会主 义思想为指导，坚定贯彻党中央决策部署，认真落实监管部门、市委市政府工作要求，牢牢把握稳中求 进工作总基调，统筹好当前稳健经营与未来可持续发展。坚持问题导向、实战导向与价值导向，系统推 进转型发展各项重点任务：聚焦关 ...

公司于审阅该决定并与其专业顾问讨论后，已于2026年2月27日提交要求以将该决定提请上市复核委员 会复核。 公司股份继续停牌。 智通财经APP讯，保集健康(01246)公布，于2026年2月13日，公司接获联交所发出的函件，当中载述联 交所上市委员会已决定根据上市规则第 6.01A(1)条取消股份的上市地位，原因是上市委员会认为公司并 未于2026年1月24日前达成所有复牌指引及并无于联交所恢复股份买卖。特别是，在复牌指引中，联交 所认为公司未能证明符合上市规则第13.24条(复牌指引3)、证明管理层诚信(复牌指引5)、内部控制审查 (复牌指引6)及披露所有重要资料(复牌指引8)。 ...

格隆汇2月27日丨中国圣牧(01432.HK)公告，截至2025年12月31日止年度(「报告期间」)，预期集团录 得母公司拥有人应占亏损介乎人民币3.5亿元至人民币3.9亿元之间，2024年集团母公司拥有人应占亏损 为人民币6550万元。集团依据相关规定及审慎性原则，就所持未开发草原土地使用权，计提减值拨备约 为人民币300百万元至人民币330百万元之间。撇除上述影响因素後，公司经营业务之亏损较上年收窄约 人民币500万元至人民币2500万元之间。 ...

Performance Summary - Xinyi Solar (00968.HK) reported a revenue of 20.861 billion yuan for 2025, a decrease of 4.8% year-on-year, with a net profit of 844.5 million yuan, down 16.2%, primarily due to a decline in average selling prices of solar glass products [2] - Zhongxin Innovation (03931.HK) expects a net profit of 2.025 billion to 2.193 billion yuan for 2025, an increase of approximately 140% to 160% compared to the previous year, driven by high growth in leading technology products across passenger, commercial, and energy storage sectors [2] - Rongchang Bio (09995.HK) anticipates a revenue of 3.251 billion yuan for 2025, an increase of 89.36% year-on-year, with a net profit of 709 million yuan, turning profitable due to increased sales of Tislelizumab and injection-use Vedolizumab [2] - Xinyi Energy (03868.HK) expects a revenue of 2.453 billion yuan for 2025, a slight increase of 0.53%, with a net profit of 1.011 billion yuan, up 27.79% [2] - Sihang Property (00083.HK) reported a revenue of 5.185 billion HKD for the six months ending December 31, 2025, an increase of 34.54%, while net profit decreased by 15.77% to 1.533 billion HKD [3] - Haohai Biological Technology (06826.HK) expects a revenue of approximately 2.473 billion yuan for 2025, a decrease of 8.33%, with a net profit of about 251 million yuan, down 40.3% [4] - Chunli Medical (01858.HK) anticipates a total revenue of approximately 1.044 billion yuan for 2025, a year-on-year increase of 29.52%, with a net profit of 272 million yuan, up 117.72% [5] - Baosheng International (03813.HK) issued a profit warning, expecting a net profit of approximately 211 million yuan for 2025, a decrease of about 57.1% [6] - Chip Intelligence Holdings (02166.HK) expects a net profit of approximately 140 million to 170 million HKD for 2025, an increase of about 40% to 70%, benefiting from the booming AI technology and increasing market demand [6] - Fengcai Technology (01304.HK) anticipates a total revenue of approximately 774 million yuan for 2025, a year-on-year increase of 28.91%, with a net profit of about 227 million yuan, up 1.92% [6] - Huayou Energy (01251.HK) issued a profit warning, expecting a loss of approximately 100 million to 150 million HKD for the 2025 fiscal year [7] - Zhoneng Group (00131.HK) reported a revenue of 272 million HKD for the six months ending December 31, 2025, an increase of 250.64%, with a net profit of 180 million HKD, turning profitable [8] - Fudan Zhangjiang (01349.HK) expects a revenue of approximately 686 million yuan for 2025, a decrease of 3.33%, with a net loss of approximately 157 million yuan, turning from profit to loss [9] Company News - Bay Area Development (00737.HK) reported that the total toll revenue for January from the Guangzhou-Shenzhen Expressway, Guangzhou-Zhuhai West Line Expressway, and the Shenzhen section of the Yangtze River Expressway was approximately 241 million, 105 million, and 75.169 million yuan, respectively, representing year-on-year growth of 15%, 17%, and 19% [10] - LeCang Logistics (02490.HK) plans to acquire two large container ships [10] - Innovent Biologics (01801) received approval for Jebatuzumab (Pimobendan) in China for the indication of relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma [11] Buyback Activities - Xiaomi Group-W (01810.HK) repurchased 2.8582 million shares for a total of approximately 99.9973 million HKD, with a repurchase price ranging from 34.92 to 35.04 HKD per share [12] - Geely Automobile (00175.HK) repurchased 3.673 million shares for approximately 59.4327 million HKD, with a repurchase price between 16.1 and 16.3 HKD [13] - Miniso Group (09896.HK) repurchased approximately 0.0526 million shares for about 1.8893 million HKD, with a repurchase price ranging from 35.64 to 36.34 HKD [14] - NetEase Cloud Music (09899.HK) repurchased approximately 0.09715 million shares for about 14.9959 million HKD, with an average repurchase price of 154.36 HKD [14]

格隆汇2月27日丨恒昌集团国际(01421.HK)公告，截至2025年12月31日止六个月，集团大部分收益源自 中华人民共和国(「中国」)的太阳能电业务、配电系统及美容及保健产品。中国太阳能电业务、配电系 统及美容及保健产品贡献的收益分别占集团总收益约52.8%(29,900,000港元)、44.9%(25,400,000港元)及 2.3%(1,300,000港元)。 公司拥有人应占亏损为约1130万港元(截至2024年12月31日止六个月：亏损1630万港元)及母公司普通股 权持有人应占的每股基本亏损为6.8港仙(截至2024年12月31日止六个月：每股亏损12.8港仙)。该变动主 要由于(i)太阳能电业务分部业绩好转产生亏损约5,700,000港元(截至2024年12月31日止六个月：亏损 8,200,000港元)；(ii)美容及保健业务分部业绩好转产生亏损1,700,000港元(截至2024年12月31日止六个 月：亏损3,000,000港元)；及(iii)公司及其他未分配开支增加至约8,600,000港元(截至2024年12月31日止 六个月：7,600,000港元)的综合影响。 ...

格隆汇2月27日丨中国高精密(00591.HK)宣布，于2026年2月27日，董事会辖下环境、社会及管治委员会 (「ESG委员会」)已告成立。执行董事邹崇获委任为ESG委员会主席；及四名独立非执行董事(即吉勤 之、胡国清、陈玉晓及黄世震)获委任为ESG委员会成员。 ...

该集团是一家即将进入商业化阶段的生物製药公司。同源康生物为一家非全资附属公司，专注于双抗、 三抗及ADC，独立于集团的核心业务及营运。增资及先前增资预计将有助于为同源康生物产生营运资 金，同源康生物是一家处于早期阶段的初创企业，预计在实现商业化之前，其在不久的将来将有大量的 资金需求。因此，该等交易将使集团能够将其资源集中于集团营运的其他方面，使集团能够更好地管理 其营运，同时保留于同源康生物的重大权益及参与程度。 智通财经APP讯，同源康医药-B(02410)公布，于2026年2月27日(交易时段后)，现有股东(包括该公司)、 同源康生物及认购人(深圳创新资本、宁波红土、衢州启真、衢州高质量发展、长兴同源及深圳国海中 恒)订立增资合同，据此，订约方同意以总代价约人民币8350万元增加同源康生物的注册资本约人民币 649万元。增资完成后，同源康生物的总注册资本将由人民币1400万元增加至约人民币2049万元，而公 司于同源康生物的权益将由约57.14%减少至39.03%，且同源康生物将不再为集团的附属公司。 ...

Core Viewpoint - The company, Yidu Tech (02158), demonstrates strong confidence in its long-term value and the prospects of the AI healthcare industry through its ongoing share buyback program, having repurchased 322,000 shares at approximately HKD 5.99 per share, totaling nearly HKD 2 million on February 27 [1] Group 1: Share Buyback Activity - Yidu Tech has completed 19 share buybacks this year, with a total expenditure exceeding HKD 76 million [1] - The buyback actions are seen as a consistent strategy to reinforce the company's commitment to its value and the AI healthcare sector [1] Group 2: Industry Insights - According to a report by Zhonghang Securities, domestic and international healthcare companies are increasingly investing in AI products and services across various areas, including medical imaging, clinical decision support, precision medicine, health management, medical information technology, drug development, and medical robotics [1] - AI is evolving from a "technical assistance" role to becoming a core driver of "value reshaping" and "efficiency revolution" in the healthcare industry, with its commercial value permeating from research to clinical, payment, and patient levels [1] Group 3: Business Developments - Yidu Tech has made significant innovations, including the internal testing of its clinical evidence-based intelligent system "Yidu Zhixun" [1] - A project supported by Yidu Tech for infectious disease monitoring and early warning in Hainan Free Trade Port has been recognized at the national level, being included in the "2025 Data Element ×" competition award project case collection [1]